Suchergebnisse - "93NS566KF7"

PubPharm (629)

1

Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia

enthalten in: Leukemia research | 2024

von Bourne, G. | Diebold, K. | Espinoza-Gutarra, M. | +6

2

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

enthalten in: Cancer reports (Hoboken, N.J.) | 2024

von Serio, B. | Grimaldi, F. | Ammirati, L. | +11

3

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

enthalten in: Blood cancer journal | 2024

von Tiong, I. | Wall, M. | Bajel, A. | +36

4

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Russell, N. | Wilhelm-Benartzi, C. | Othman, J. | +117

5

Pediatric acute myeloid leukemia - novel approaches

enthalten in: Current opinion in hematology | 2024

von Karol, S. | Gueguen, G.

6

Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2024

von Ladror, D. | Gu, C. | Tong, V. | +4

7

Harnessing autologous immune effector mechanisms in acute myeloid leukemia : 2023 update of trials and tribulations

enthalten in: Leukemia research | 2023

von Patel, S. | Bello, E. | Wilks, A. | +3

8

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML : the UK NCRI AML18 trial

enthalten in: Blood | 2023

von Freeman, S. | Thomas, A. | Thomas, I. | +19

CommentIn: Blood. 2023 Nov 16;142(20):1673-1674. - PMID 37971761

9

Gemtuzumab ozogamicin in AML : the next chapter

enthalten in: Blood | 2023

von Röllig, C.

CommentOn: Blood. 2023 Nov 16;142(20):1697-1707. - PMID 37595359

10

A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML) : evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Marcelletti, J. | Sikic, B.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[63]